Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Merck (MRK) announced the presentation of “positive” results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug ...

US pharma giant Merck & Co (NYSE: MRK) has presented positive results from two pivotal Phase III trials of the ...

Fintel reports that on March 14, 2025, B of A Securities downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from ...

being held in San Francisco and were featured in a CROI press conference. Merck plans to begin submitting applications for marketing authorization to regulatory agencies by mid-2025. In the double ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company's EMBRACE phase IIb study.1 The ...

ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating that tecovirimat did not improve mpox resolution. The results from STOMP ...

Sanofi is tapping San Francisco-based Atomwise for a new AI ... some of the biggest names in pharma and medicine, including Merck & Co, Eli Lilly, and AbbVie. In 2019 they struck a major deal ...

When Kamala Harris became VP, her husband, Doug Emhoff, made history as the nation's first-ever second gentleman, but not all ...

Merck says the expansion in Durham is part of more than $12 billion the company has invested in U.S. manufacturing and ...